Summary This study reports a significant decrease in ageadjusted incidence rates of hip fracture for women in Oslo, Norway, even compared with data from 1978/1979. Use of bisphosphonate may explain up to one third of the decline in the incidence. Introduction The aims of the present study were to report the current incidence of hip fractures in Oslo and to estimate the influence of bisphosphonates on the current incidence. Methods Using the electronic diagnosis registers and lists from the operating theaters of the hospitals of Oslo, all patients with ICD-10 codes S72.0 and S72.1 (hip fracture) in 2007 were identified. Medical records of all identified patients were reviewed to verify the diagnosis. Age-and gender-specific annual incidence rates were calculated using the population of Oslo on January 1, 2007 as the population at risk. Data on the use of bisphosphonates were obtained from official registers. Results A total number of 1,005 hip fractures, 712 (71%) in women, were included. The age-adjusted fracture rates per 10,000 for the age group >50 years were 82.0 for women and 39.1 for men in 2007, compared with 110.8 and 41.4 in 1996/1997, 116.5 and 42.9 in 1988/1989, and 97.5 and 34.5 in 1978/1979, respectively. It was estimated that the use of bisphosphonates may explain up to 13% of the decline in incidence in women aged 60-69 years and up to 34% in women aged 70-79 years. Conclusions The incidence of hip fractures in women in Oslo has decreased significantly during the last decade and is now at a lower level than in 1978/1979. This reduction was not evident in men. The incidence of hip fractures in Oslo is, however, still the highest in the world.
Introduction
Hip fracture represents an important cause of morbidity, mortality, and health care costs [1] [2] [3] . The incidence of hip fractures in Oslo increased during the late 1970s and 1980s, but leveled off in the 1990s. Still, the incidence in 1996/ 1997 was the highest ever reported [4] . Recent reports from Western countries differ in whether the incidence is increasing, stable, or decreasing [5, 6] . However, the population in industrialized countries is growing older and an increased number of hip fractures can therefore be expected even if the age-specific incidence remains unchanged or decreases [7] . Osteoporosis is an important factor in the pathogenesis of hip fractures. Bisphosphonates have been shown to reduce the incidence of hip fractures in osteoporotic patients with 40% [8, 9] . The effect in a population not taking part in a randomized controlled trial is, however, uncertain [10] . Bisphosphonates are now the most widely used antiosteoporotic drugs [11] after introduction on the Norwegian market in 1996.
The high incidence of hip fractures in Oslo has been followed closely during the previous three decades [4, 12, 13] . The aim of the present study was to report the current incidence of hip fractures in Oslo to elucidate whether there has been a change during the last decade, and to compare this incidence with recent data from other countries. In addition, the influence of the use of bisphosphonates on the incidence of hip fractures was estimated.
Materials and methods

Study population
Patients in Oslo sustaining a hip fracture in 2007 were referred to one of four hospitals. All patients with the International Classification of Diseases (ICD-10) codes S72.0 (cervical fracture) and S72.1 (trochanteric fracture) from January 1 through December 31, 2007 were identified using the electronic diagnosis registers of the four hospitals. The related diagnoses S72.2 (subtrochanteric fracture), S72.7, S72.9, T02.3, T02.5, T02.6, T02.7, T02.8, T02.9, and T12 were also reviewed to identify additional patients with a hip fracture. The lists from the operating theaters of the hospitals were reviewed to identify patients with a hip fracture that was not identified in the electronic search. Medical records for all patients were reviewed and the diagnoses verified. If the medical records were inconclusive, the diagnosis was verified by review of radiographs and corresponding reports. Patients residing in the city of Oslo with a new hip fracture in 2007 were included. Exclusion criteria were: fracture distal to the lesser trochanter; isolated fracture of the greater trochanter; and fracture due to cancer metastases. Patients with two different fractures within the observation period had both recorded. Patients admitted to more than one hospital for the same fracture were only recorded at the hospital where the primary surgery was performed.
Gender, date of birth, date of hip fracture, type and side of hip fracture, place of trauma, and previous hip fractures were recorded. The fractures were classified as either cervical or trochanteric according to the description in the medical record or review of radiographs.
Historical and international comparison
Using the population of Oslo on January 1, 2007 [7] as the population at risk, the age-and gender-specific annual incidence rates were calculated. These rates were compared with those of Oslo in 1996/1997 [4] , 1988/ 1989 [13] , and 1978/1979 [12] . In order to make an international comparison of hip fracture incidence, searches in Medline and EMBASE for "hip fracture and incidence" from January 1, 2000 to December 12, 2010 were performed. Heading and abstract were examined to identify articles that were original reports on incidence rates in a defined geographical area. Incidence rates were calculated from the articles providing sufficient data for comparison by standardizing to the population of Oslo on January 1, 2007.
Influence of immigration
A sensitivity analysis was conducted to elucidate the influence of immigration on incidence. This was done by assuming that all of the fractures occurred among ethnic Norwegians and that only ethnic Norwegians made up the total population in every age group. Data from Statistics Norway were used to conduct the analysis [7] .
Influence of bisphosphonates
Bisphosphonates were introduced to the Norwegian market in 1996, and therefore the population of Oslo in 1996/1997 was unexposed to bisphosphonates. The difference in percent in the incidence of hip fractures in our study population (age groups of women in Oslo 2007) if no one used bisphosphonates, compared with the same population using bisphosphonates, was calculated. This calculated percentage decline in the incidence of hip fractures attributable to bisphosphonates was then compared with the observed percentage decline in the incidence of hip fractures in the population study.
The registration of bisphosphonates sold in defined daily doses (DDD) was obtained from the Norwegian register on drug consumption based on sale from wholesalers including sales to non-pharmacy outlets [14] . Number, age, and sex of users of bisphosphonates were collected from the Norwegian Prescription Database, established January 1, 2004, which contains data on the users of drugs dispensed by prescription in Norway [15] . The use of bisphosphonates among women in Oslo showed a minor increase from 1.4% to 2.0% of the population ≥50 years from 2004-2007 [15] and the mean for the 3 years before 2007 was used to obtain a conservative estimate: 4% of females aged 60-69 and 10% of those aged 70-79 used bisphosphonates in the years 2004-2006. In Norway, prescription of bisphosphonates covered by public reimbursement is restricted to patients with established osteoporosis, requiring a T-score of ≤−2.5 in addition to a low-energy fracture. Of all bisphosphonates prescribed in 2006, 98.1% were covered by public reimbursement [15] . On this background, it was assumed that all users of bisphosphonates had osteoporosis.
The material of Falch and Meyer from Oslo 1996 [16] was used to estimate the number of individuals in Oslo with osteoporosis in each age group. This gave a proportion of females with osteoporosis (T-score ≤−2.5) of 20% in the age group 60-69 years and 28% in the age group 70-79 years. According to Kanis et al. from Bone 2000 [17] , the risk of hip fracture among women with T-score ≤−2.5 is 4.9 times higher in females aged 65 years (used for the age group 60-69 years) and 4.7 times higher in females aged 75 years (used for the age group 70-79 years), than those with T-score >−2.5. Furthermore, the use of bisphosphonates may reduce the risk of a hip fracture by 40% [18] , reducing the increased risk in treated osteoporotic women aged 60-69 years from 4.9 to 2.9 times higher than in those with T-score >−2.5 and from 4.7 to 2.8 in women aged 70-79 years. These figures were used to estimate the difference in risk between an untreated population and a population where 4% (all of them with osteoporosis) of 60-69-year-old women and 10% (all of them with osteoporosis) of 70-79-year-old women used bisphosphonates.
The estimated decline in incidence due to use of bisphosphonates was compared with the observed decline in incidence in the respective age group in order to calculate the fraction of decline in incidence that bisphosphonate use may explain. Analysis on use in the age group >80 years was not possible due to lack of reference material, and analysis in the age group 50-59 years was not performed due to the small number of fractures.
Statistics
The level of statistical significance was set at 0.05. Results are given as mean (95% confidence interval (CI)) unless otherwise stated. Age is given as median with 95% CI for median. Two sample t test or Mann-Whitney U test was used for comparisons between genders. Chi-square test was used to compare cervical and trochanteric fractures. Comparisons of age-adjusted incidence rates were performed by calculating the CI as described by Armitage and Berry [19] . Analyses were conducted using SPSS18, PASW Statistics, unless otherwise stated.
Ethics and approvals
The study was approved by the Regional Committee for Research Ethics, the Norwegian Directorate of Health, and the Local Data Inspectorate.
Results
Patient characteristics and incidence
A total of 1,005 hip fractures were verified in 985 patients. Twenty patients (17 women) had fractures of both hips in different episodes. The median age of fracture was 85 years (95% CI 84-85) in women and 81 years (95% CI 79-82) in men (p<0.001), and 712 (71%) of the fractures occurred in women (p<0.001 vs. men). The number of patients with a previous hip fracture was 110 (15.4%) among women compared with 22 (7.5%) in men (p00.001). An exponential increase in the incidence of hip fracture with age was observed in both genders (Fig. 1, Table 1 ). The numbers of cervical and trochanteric fractures were 596 (59.3%) and 409 (40.7%), respectively (p<0.001). There was no difference in the number of fractures on the left (n0511, 51.5%) and right side (p00.41).
Of all the fractures, 92% occurred after low impact injury defined as falling from standing height or lower. Most injuries (73%) occurred indoors, including 37% in the patient's own home, 27% in a care facility, 5% in hospital, and 4% in other places indoors. Only 16% of the fractures occurred outdoors. In 10% of the fractures, the place of injury had not been recorded.
Historical and international comparison
For the age group 50 years and older, the age-and genderspecific incidence rates of hip fractures for women in Oslo declined significantly not only during the last decade, but also compared with the rates reported in the late 1970s, with a reduction from 1996/1997 to 2007 of 25% and from 1978/ 1979 to 2007 of 16% ( Table 2 ). The reduction was not evident among men. The literature search identified 1,408 articles on "hip fracture AND incidence", and 108 articles were found eligible for further review. In eight studies, sufficient data were provided allowing the standardized comparison (Table 3 ) [20] [21] [22] [23] [24] [25] [26] [27] . The fracture incidence of Oslo is still higher than reported elsewhere.
Influence of immigration
Results from the sensitivity analysis regarding effect of the immigrant population demonstrated that the calculated age-adjusted incidence rates for women still showed a significant reduction in 2007 compared with rates from 1996/1997 and 1988/1989, even when it was assumed that none of the fractures were in the immigrant population. The reduction from 1978/1979 to 2007 was no longer statistically significant, but the tendency of decreasing rates was still present.
Influence of bisphosphonates
The risk reduction estimated by the analysis of bisphosphonate use showed that bisphosphonates could explain a 4% reduction in hip fracture rate for women in the age group 60-69 years and a 9% reduction in the age group 70-79 years. This could in turn explain up to 13% of the total reduction from 1996/1997 to 2007 in the age group 60-69 years and up to 34% of the total reduction from 1996/ 1996 to 2007 in the age group 70-79 years for women from 1996/1997 to 2007. The relationship in time between sale of bisphosphonates and hip fracture incidence is illustrated in Fig. 2 .
Discussion
Age-adjusted hip fracture incidence rates decreased significantly for women in Oslo, not only during the last decade but also compared with rates of the 1980s and 1970s. A similar decrease was not evident in men. For women, the decrease was substantial in all age groups. Still, the age-adjusted incidence rates in Oslo for women and men are the highest in the world. The majority of the fractures were the result of a low-energy trauma sustained indoors.
A hip fracture is a result of (1) a trauma to the bone and (2) a bone with a quality that cannot withstand the impact of the trauma. The trauma is commonly due to fall from standing height [28] . This has led to the development of fall preventive measurements and hip protectors. Hip protectors may prevent fracture when used, but adherence to use is low [29] . To our knowledge the work on fall prevention has not been intensified in Oslo from 1997 to 2007. However, data on factors known to affect frequency of fall, e.g., use of medication, are not easily available. This makes it difficult to reveal whether the frequency of trauma has influenced the observed changes of hip fracture incidence.
Regarding reduced bone quality, the most important reason for fragile bone in the elderly is osteoporosis. Hence, reduced incidence of hip fracture might reflect a reduction of osteoporosis in the community. Changes in specific risk factors for osteoporosis such as low intake of vitamin D and calcium are not readily available for the population of Oslo, especially not in the older age groups. This is also the case for other nutritional risk factors as well as the use of alcohol and smoking. Smoking has, however, decreased in the general population and one could speculate if this may have contributed to the decline in hip fracture incidence.
Low bone mineral density (BMD) is another risk factor for osteoporosis and hip fracture. Cooper and coworkers have shown that birth weight is correlated with BMD later in life [30] . This is thought to be a result of intrauterine programming under which endocrine responses are adjusted to nutritional availability during pregnancy. The median age of female hip fracture patients in 2007 was 85 years. Hence, many of the patients were born in the 1920s and were children and adolescents during the 1930s and 1940s. This concurs with the end of the demographic transition in Norway, when both death rates and birth rates were falling due to a rise in the standard of living [7] . Data on changes in birth weight in Norway in the early twentieth century are not available. The improved standard of living in this period may, however, imply better nutrition during pregnancy with the likely effect of increased birth weight compared to those being born during World War I, thereby having an effect on peak bone mass in this population. Better nutrition in childhood and adolescence would further contribute to an increased peak bone mass. This could be a part of the explanation for the reported decline in incidence rates in several Western countries, as well as in the present study.
Low body mass index (BMI) is also a known risk factor for hip fracture and osteoporosis, partly due to the effect on BMD, but the lack of fat padding over the trochanteric region could also increase the risk. A substantial increase in BMI has been observed in the adult Norwegian population [31] , which might contribute to the decreasing incidence of hip fracture. Data on the elderly are not readily available, but self-reported anthropometric data from national health surveys in 1998 and 2008 revealed no change in BMI [32, 33] , which could indicate that the elderly population is less affected by the weight changes than the rest of the population. Changes in the use of bisphosphonates and hormone replacement therapy (HRT) in the population at risk may also have contributed to changes in the incidence of fractures. Bisphosphonates were introduced to the Norwegian market in 1996, therefore the use before 1996/1997 is negligible and the current use of bisphosphonates could provide part of the explanation for the reduced incidence of hip fractures. The effect of HRT on reducing osteoporotic fractures is strongest when use is closest in time, and 5 years after last use the effect is negligible [34] . Meyer et al. estimated that half of the reduction in forearm fractures in young postmenopausal women in Oslo in the period from the 1970s to 1990s could be due to use of HRT [35] . The register on sale from wholesalers reported an average sale of HRT of 12,000 DDD/year in the 3 years before 1997. Ten years later the corresponding number was 8,500. The reduced use of HRT in the last decade might in fact therefore counteract the decrease in hip fracture incidence, rather than be part of the explanation.
Because of immigration, the demographic changes in Oslo during the last decade have been considerable. The percentage of men over 50 years from outside Europe and North America has increased from 6% in 1998 to 11% in 2008 [7] . For women the corresponding increase was from 3% to 8%. The sensitivity analysis indicated that the lower incidence of hip fracture in persons from outside Europe is unlikely to be a major reason for the reduction of incidence rates. This is due to the age distribution of the immigrant population where few have yet reached older age, corresponding with the finding of Lofthus et al. on distal forearm fractures in Oslo [36] .
Despite the declining incidence of hip fracture in women, Oslo is still the geographical region with the highest incidence reported. It is known from previous studies that Scandinavia, and Oslo in particular, has a high incidence of hip fracture [4, 37] . The reason for this is not well understood, but genetical influence on skeletal geometry and bone mineral density are possible explanations [37] . The observed decrease in incidence in Oslo corresponds with other recent reports from Western countries [5, 38] . The present study is the only one with consistent methodology carried out over four decades, thereby consolidating the finding of decreasing incidence. Other authors conclude that the reason for the reduced incidence remains unknown. This study from Oslo suggests that the use of bisphosphonates may be part of the explanation.
A previous study from Oslo showed that register data were not reliable as the single source of information because of incomplete registration [39] . The present study used several sources for identifying and validating data. The diagnosis of hip fracture is easy to make and almost all patients are operated. Still, data from one of the hospitals indicated that some patients with a previous fracture incorrectly had been given the diagnosis of new hip fracture, and chart review was essential for correct registration. The strength of the present study is that comparable methods were used for collecting data in Oslo every decade for 30 years. The only variation in the methodology consists of the lack of electronic data registers (manual registers were used) in the two oldest studies, and in these studies data were collected for two, not 1 year. It is therefore not likely that the reduced incidence demonstrated is due to methodological variations. The relatively small number of fractures is, however, a limitation of this study, particularly for analyses related to males. Larger geographical areas or data collection over a longer period of time would have improved the statistical power. Furthermore, individual data on risk factors for hip fractures and osteoporosis were not recorded, making it unsuitable for establishing causes of the observed decline in hip fracture incidence.
In conclusion, the incidence of hip fracture is declining in Oslo, Norway among women, but not among men. Bisphosphonate use may be part of the explanation for the decline, but there is a need for studies that can further elucidate this issue. Because the population is growing older, and the incidence of hip fracture is highest in the older age groups, the actual number of hip fractures may continue to increase despite the decrease in incidence. Prevention of hip fractures is therefore still of outmost importance.
